



The Gulf Coast Consortia's High Throughput Research and Screening Center at the IBT

Peter Davies, MD, PhD
Program Director
pdavies@tamu.edu

Clifford Stephan, PhD
Scientific Director
cstephan@tamu.edu



**INSTITUTE OF BIOSCIENCES
AND TECHNOLOGY**
TEXAS A&M UNIVERSITY

GCC Consortium for Innovative Drug Discovery and Development (IDDD)

High Throughput Flow Cytometry



Specialized high-throughput flow cytometers
Texas A&M IBT
CPRIT Funding RP190581

Combinatorial Drug Discovery Program



Drug repurposing and combination drug discovery
Texas A&M IBT
CPRIT Funding RP200668

Targeted Therapeutics Drug Discovery Program



Chemistry-based strategies to discover novel, targeted cancer therapeutics
University of Texas, Austin
CPRIT Funding RP210088

Center for Drug Discovery




DNA-encoded chemistry and metabolomics
Baylor College of Medicine
CPRIT Funding RP160805

By seamlessly sharing access to critical resources across institutional boundaries, the network can provide the most efficient and effective support for the development of new cancer therapeutics



Advanced Microscopy & Imaging Informatics



Advanced imaging platforms and informatics for cancer-related drug discovery research
Baylor College of Medicine
CPRIT Funding 170719

Microphysiological Lead Optimization & Toxicity Screening



Identifying & de-risking lead op compounds
Texas A&M IBT
CPRIT Funding RP210108

Therapeutic Monoclonal Antibody Lead Optimization



Specialized expertise in the development of engineered monoclonal antibodies
University of Texas Health Science Center, Houston
CPRIT Funding RP190561

Comprehensive PK/PD & Formulation




PK/PD evaluations and dosage formulations
Texas Southern University
CPRIT Funding RP180748

Accelerator For Cancer Therapeutics





Cancer therapeutics accelerator with advanced computational resources
Texas Medical Center and University of Texas Medical Branch
CPRIT Funding RP190674

GCC Drug Discovery Cores at the Texas A&M IBT



GCC Drug Discovery Cores at the Texas A&M IBT



GCC Drug Discovery Cores at the Texas A&M IBT


Each of the Cores is:

- A unique, highly productive multi-institutional screening resource
- Available to academic, private, and corporate investigators
- Easily accessible – Your neighbor in the Texas Medical Center located in the Texas A&M Institute of Biosciences and Technology
- Part of the GCC, the organization that lowers the barriers to collaboration for the member institutions


IBT Combinatorial Drug Discovery Program

- **Assay development and pilot screens**
 - Bench to HTS
 - Grant support
- **Single agent screens**
 - Probe identification and Mechanism of action studies
 - Focused screens
- **Combinatorial screens – “Repurposing”**
 - Identifying therapeutic leads that can be rapidly advanced to preclinical and clinical evaluation
 - Multi-component drug combinations (cocktails)
 - Targeted agents overcoming resistance or lowering toxicity
- **Secondary analysis**
 - Pharmacogenomics/transcriptomics analysis
 - Biostatistics, conventional modeling, and deep learning


CDDP Target-Based & Phenotypic Drug Discovery Model Systems




Proteins (enzymes)




Cells



Spheroids



Organoids



Tissue Chips



Simple model organisms

CDDP Drug and Compound Collections

Library Focus	Library Focus
Approved Drug Library	Stem cell Differentiation Compound Library
	Cell cycle related compound Library
Oxidation-Reduction Compound Library	Apoptosis Compound Library
Anti-Metabolism disease Compound Library	Autophagy Compound Library
Mitochondrial Targeting Compound Library	DNA Damage _ Repair Compound Library
Epigenetics Compound Library	Ion Channel Inhibitor Library
	Endocrinology-Hormones Library
PI3K-AKT-mTOR Compound Library	Neuronal Signaling Compound Library
MAPK Inhibitor Library	
Tyrosine kinase inhibitor library	JAK STAT Compound Library
	Wnt_Hedgehog_Notch Compound Library
Selleck Bioactives Collection	
	Fluorochemical Library
Prestwick/Microsource Collections	Natural Compound Library

**CDDP maintains a collection of drugs and investigational agents approved for use in humans, bioactive compounds, natural products, and some small molecules.
The Core maintains > 35,000 testable agents.**

High Throughput Flow Cytometry Program - HtFCP



Services provided with automated HT flow cytometry for drug discovery:

- **Speed:** automated HT drug screening in hours vs days
- **Scalability:** can run large scale drug screens > 9,000 samples/day
- **Customized projects:**
 - Ability to multiplex endpoints
 - Detection of extracellular vesicles, exosomes, and nanoparticles (LOD 0.2 μ m)
 - Informatics analysis with machine learning and AI

Major equipment:

Bio-Rad ZE5 High Throughput Flow Cytometer

- 5 laser and 30 detectors
- Continuous 24hr sampling from tubes or multiwell plates

BD Biosciences FACSFusion Cell sorter

- 4 lasers (405 nm, 488 nm, 561 nm, and 640 nm) and 15 filters
- BSL2 level sorting of single cells into bulk tubes or 96 well plates

Cytek Aurora Spectral Flow Cytometer

- 3 lasers (488, 567, and 640 nm) and 32 fluorescent channels
- full imaging spectral flow cytometry

BioRad ZE5 cell analyzer



Microphysiological Lead Optimization & Toxicity Screening - MLOTS


Drug Discovery and Development Pipeline



- Current CPRIT-Funded resources for drug discovery in the Texas Medical Center and the region.
- MLOTS fills a perceived void in the pipeline for efficacy testing in 3D and microfluidic models and early toxicity testing (CV, CNS, Liver)


Microphysiological Lead Optimization & Toxicity Screening - MLOTS

MLOTS - 3D Model Efficacy Testing for Lead Optimization




Cellular Spheroids

- Hanging drop
- Ultralow attachment
- n3D Magnetic beads



Cellular Organoids

- Cells cultured in ECM
- Stem cell focused



Microfluidic, Multicellular Models

- High throughput (96/64/48 well)
- Vascularized organoids

Microphysiological Lead Optimization & Toxicity Screening - MLOTS

MLOTS – Fail Early/Tox Identification Testing for Lead Optimization

Liver Toxicity Testing – Initial Model

> [Toxicology](#). 2021 Feb 28;450:152667. doi: 10.1016/j.tox.2020.152667. Epub 2021 Jan 6.

A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®


Kristin M Bircsak¹, Richard DeBiasio², Mark Miedel², Alaa Alsebah³, Ryan Reddinger³, Anthony Saleh³, Tongying Shun², Lawrence A Vernetti², Albert Gough⁴

Affiliations + expand


PMID: 33359578 DOI: [10.1016/j.tox.2020.152667](#)



Multi-well plate format
96 'Chips'/plate




Multi-cellular
Vascular channel
with perfusion



Mimetas Technology Platform


2-lane OrganoPlate®
culture cell design

ECM in	medium in/out	tissue area	medium in/out
-----------	------------------	----------------	------------------








A




B





C




D




E

Continuous bi-directional flow



IBT Mimetas Imaging Automation Platform



The Mimetas Microfluidic Platform – Neural Applications

Open Access | Published: 09 December 2016



High-throughput compound evaluation on 3D networks of neurons and glia in a microfluidic platform

[Nienke R. Wevers](#), [Remko van Vught](#), [Karlijn J. Wilschut](#), [Arnaud Nicolas](#), [Chiwan Chiang](#), [Henriette L. Lanz](#), [Sebastiaan J. Trietsch](#), [Jos Joore](#) & [Paul Vulto](#)

Scientific Reports 6, Article number: 38856 (2016) | [Cite this article](#)

11k Accesses | 85 Citations | 15 Altmetric | [Metrics](#)

PMID: 27934939



The Mimetas Microfluidic Platform – Neural Applications

Open Access | Published: 09 December 2016

High-throughput compound evaluation of neurons and glia in a microfluidic platform

Nienke R. Wevers, Remko van Vught, Karlijn J. Wilschut, J. Lanz, Sebastiaan J. Trietsch, Jos Joore & Paul Vulto

Scientific Reports 6, Article number: 38856 (2016) | [Cite this article](#)

11k Accesses | 85 Citations | 15 Altmetric | [Metrics](#)

The OrganoPlate® supports growth and differentiation of various cerebral cell types.






Maximum projections of immunofluorescent images:

(a) A co-culture of mature iCell® neurons (β 3-tubulin) and astrocytes (GFAP) at day 14.

(b,c) Axol Huntington neural stem cells have differentiated into neurons and astrocytes @ 6wks


(d) Axol neural stem cells show both glutamatergic (vGLUT) and GABAergic (vGAT) neurons @ 6 wks

(e) Dopa.4U™ neurons at day 5



The Mimetas Microfluidic Platform – Neural Applications


Modeling ischemic stroke in a triculture neurovascular unit on-a-chip

Nienke R. Wevers , Arya Lekshmi Nair, Tania M. Fowke, Maria Pontier, Dhanesh G. Kasi, Xandor M. Spijkers, Charlie Hallard, Gwenaëlle Rabussier, Remko van Vught, Paul Vulto, Helga E. de Vries & Henriëtte L. Lanz


Fluids and Barriers of the CNS **18**, Article number: 59 (2021) | [Cite this article](#)

3339 Accesses | 1 Citations | 7 Altmetric | [Metrics](#)





PMID: 34906183



3-Lane Plate



40 Chips/Plate



Microphysiological Lead Optimization & Toxicity Screening - MLOTS

MLOTS – Fail Early/Tox Identification Testing for Lead Optimization


Cardiovascular and CNS



MAESTRO PRO




action potential morphology & characterization




cardiac field potential

Mean Firing Rate = # of Spikes / Time




Activity

Connectivity



Synchrony

Bursts of Action Potentials



Oscillation

iPSC cardiovascular and neuronal cells

Neural – Measure the key parameters of neural network function, including activity (functional), synchrony (synapses), and oscillation (networks).

Cardiac – Record the four key measures of functional cardiac performance, label free and in real time in multiwell plates: action potential (LEAP assay); field potential; propagation; and contractility.





MEA Viability – orthogonal measure


Impedance to track cell growth and morphology in real-time

Microelectrode Array (MEA) Technology Platform


Axion MEA plate features allow real-time, label-free, and noninvasive electrophysiological assays:

- Up to 768 low-noise electrodes per plate
- Recording or stimulation capability for each electrode
- Integrated, independent ground electrodes
- Conical shaped wells, optical plate bottoms
- CO₂ + Evaporation-reducing lids with humidity chambers


Electrode/ well	Electrode layout*
64 PEDOT CytoView MEA 6	
16 PEDOT CytoView MEA 24	
16 PEDOT CytoView MEA 48	
8 PEDOT CytoView MEA 96	



Human Cortical Neuron Morphology Cultured on CytoView MEA Plates




- Day 4 in culture
- 4X magnification
- Cells confined to the area indicated by the dotted line surrounding the grid of circular electrodes.



- Day 4 in culture
- 10X magnification
- Branching and neurite outgrowth is visible
- Optical bottoms allow for continuous cell monitoring

Record and Analyze Activity Using the Axion Neural Module Software



- Advanced algorithms for:
 - burst detection
 - stimulation-evoked activity analysis
- Generates plate map visualizations, raster plots, and synchrony cross-correlograms.
- Analyze/visualize single unit activity from sorted spikes.
- Explore high resolution rasters, analyze single unit participation in network events
- Characterize the response of single units to chemical, electrical, or optical stimulation.

Published Neuronal Applications from Axion Biosystems Internet Site

Development of a human derived induced pluripotent stem cell neuronal assay for early *in vitro* detection of seizure liability

K L Rockley¹; R A Roberts¹; M J Morton¹

¹Apconix, Alderley Park, Alderley Edge, Cheshire, UK



**Identifying Seizures with MEA:
Complementary Human and Rat Neuronal Models Enhance Predictivity**

You Feng, Jenifer Bradley, Sergiy Viatchenko-Karpinski, and Christopher Strock
Cyprotex US, LLC, an Evotec Company, Watertown, MA.

<https://www.cyprotex.com/toxicology/neurotoxicity/eciphneuro/>

Derivation of peripheral nociceptive, mechanoreceptive, and proprioceptive sensory neurons from the same culture of human pluripotent stem cells

Saito-Diaz K, Street JR, et al. Stem Cell Reports. (2021) PMID: 33545066


Multi-electrode array of sensory neurons as an *in vitro* platform to identify the nociceptive response to pharmaceutical buffer systems of injectable biologics

Eaton M, Que Z, et al. Pharmaceutical Research. (2021) PMID: 34244893

Inhibition of sodium conductance by cannabigerol contributes to a reduction of dorsal root ganglion neuron excitability

Ghovanloo M-R, Estacion M, et al. British Journal of Pharmacology. (2022) PMID: 35297036

IBT High Throughput Research and Screening Center “Our Team”



Specialized Expertise – “*The Heart of the Core*”

**Scientific and Technical Staff:
*Industry level HTS, Imaging and Data Analysis,
Informatics, Robotics, Automation, Tissue culture***



**TMC³
Campus**



1Q23 Collaborative
Research Building

The Combinatorial Drug Discovery Core

Peter Davies, MD, PhD
Program Director
pdavies@tamu.edu

Clifford Stephan, PhD
Scientific Director
cstephan@tamu.edu

<https://ibt.tamu.edu/cores/high-throughput>



Main



**INSTITUTE OF BIOSCIENCES
AND TECHNOLOGY**
TEXAS A&M UNIVERSITY

Funding from CPRIT: RP190581, RP200668, RP210108